A Safe and Effective Bivalent Vaccine Candidate Against Duck Enteritis Virus and Duck-Origin Novel Goose Parvovirus.

Since 2015, duck-origin novel goose parvovirus (NGPV) has caused severe economic losses to the Chinese duck industry, with no licensed vaccines or treatments available. Our previous study constructed a recombinant duck enteritis virus (rDEV) from an attenuated vaccine strain, which conferred full protection against virulent DEV challenge. NGPV VP2 is the major immunogenic structural antigen. In this study, we generated a recombinant virus rNGPV VP2-Cre by inserting the NGPV VP2 gene into the rDEV genome. VP2 expression and virus-like particle assembly were confirmed. Safety and efficacy were evaluated in ducklings. The results showed that rNGPV VP2-Cre was safe, facilitated clearance of NGPV and provided strong protection against challenge with a highly virulent DEV strain. In summary, rNGPV VP2-Cre represents a promising bivalent vaccine candidate for concurrent control of DEV and NGPV infections.